A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age
Nicola P. Klein, Paula Peyrani, Kari Yacisin, Nicole Caldwell, Xia Xu, Ingrid L. Scully, Daniel A. Scott, Kathrin U. Jansen, William C. Gruber, Wendy Watson
Topics & Concepts
Pneumococcal conjugate vaccineMedicineImmunogenicityVaccinationAdverse effectSerotypeTiterRandomized controlled trialInternal medicineGeometric meanPneumococcal vaccineImmunologyImmune systemPediatricsStreptococcus pneumoniaeAntibodyBiologyAntibioticsMicrobiologyMathematicsStatisticsPneumonia and Respiratory InfectionsRespiratory viral infections researchAdvanced Causal Inference Techniques